← FDA DRUG APPROVALS

FDA ANDA · ANDA075477

GABAPENTIN

Sponsor: CSPC OUYI

APPLICATION
ANDA075477
TYPE
ANDA
ORIGINAL APPROVAL
2005-03-23
LATEST ACTION
2024-10-11
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

GABAPENTINPrescription
GABAPENTIN 400MG · CAPSULE · ORAL
GABAPENTINPrescription
GABAPENTIN 100MG · CAPSULE · ORAL
GABAPENTINPrescription
GABAPENTIN 300MG · CAPSULE · ORAL

Approval history

2024-10-11Labeling · Supplement 8 · standardAP
2024-10-11Labeling · Supplement 10 · standardAP
2024-10-11Labeling · Supplement 9 · standardAP
2015-11-04Labeling · Supplement 6AP
2006-01-31Labeling · Supplement 2AP
2005-03-23OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →